Skip to content

BioRestorative Therapies, Inc.

BRTX

CIK 0001505497

← back to feed
Revenue (TTM)
$363.27K
−10.3% YoY Q1 May 2026
Net Income (TTM)
−$13.19M
−58.6% YoY Q1 May 2026
EPS Diluted (TTM)
−$1.39
−36.2% YoY Q1 May 2026
Gross Margin
91.9%
Q1 May 2026
Operating Margin
-4,186.3%
Q1 May 2026
Net Margin
-3,630.6%
Q1 May 2026
Free Cash Flow (TTM)
−$11.58M
Q1 May 2026
Cash
$3.11M
Q1 May 2026
Total Debt
$153.68K
Q1 May 2026
Shares Outstanding
25.48M sh
Q1 May 2026

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings